OR WAIT 15 SECS
“The ARIEL3, NOVA, and SOLO-2 trials have definitely changed how we practice and treat patients with ovarian cancer," said Dr. Jackson.
The addition of PARP inhibitors, such as olaparib and niraparib, to the maintenance treatment of patients with recurrent, platinum-sensitive ovarian cancer has led to significant progression-free survival (PFS), according to Amanda L. Jackson, MD. THE PFS benefit with these agents were demonstrated in the phase 2 SOLO-2, NOVA, and ARIEL3 trials, respectively.
“The ARIEL3, NOVA, and SOLO-2 trials have definitely changed how we practice and treat patients with ovarian cancer. We know that there is a role for PARP maintenance [in these patients], because it seems to increase the time until they recur,” said Jackson. “In the frontline setting, hopefully, [PARP maintenance will] push even more patients into permanent remission. These studies help us see that all our patients benefit from a PARP inhibitor. It's just figuring out what's the best time to give it to them.”
To learn more about the impressive results and findings, visit OncLive.